What is AKSO HEALTH GROUP's earnings per share (EPS)?

AKSO HEALTH GROUP (AHG) reported diluted earnings per share of $-0.16 for fiscal year 2025. This represents a -128.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

AKSO HEALTH GROUP Financials

AHG

Source SEC Filings (10-K/10-Q) Data as of Sep 30, 2025 Currency USD FYE March

This page shows AKSO HEALTH GROUP (AHG) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AHG FY2025 2026-04-22

Akso Health Group’s visible engine is balance-sheet expansion, with cash built mainly from financing rather than from the underlying business.

From FY2024 to FY2025, cash nearly doubled from $85.2M to $176.2M. At the same time, operating cash flow stayed near flat at only $1.4M and $1.2M, so the liquidity improvement reflects financing rather than operating cash generation.

The balance sheet is light on liabilities—just $15.8M against $215.0M of assets in FY2025—so solvency is not the immediate constraint. Compared with FY2023, this is a shift to a cash-heavy balance sheet, changing the main operating question from survival to capital efficiency.

FY2025’s reported loss looked much worse than the cash picture: net loss was -$135.0M, yet free cash flow stayed positive at $1.0M. The flip side is that gross profit was slightly negative in FY2025, so positive cash flow did not come from a healthy core margin structure.

Financial Health Signals

Financial Health Score 56/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of AKSO HEALTH GROUP's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Safe

45.71

AKSO HEALTH GROUP scores 45.71, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.3B) relative to total liabilities ($15.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

AKSO HEALTH GROUP passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Mixed

-0.01x

For every $1 of reported earnings, AKSO HEALTH GROUP generates $-0.01 in operating cash flow ($1.2M OCF vs -$135.0M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$14.8M

YoY+512.1%

5Y CAGR+16.4%

AKSO HEALTH GROUP generated $14.8M in revenue in fiscal year 2025. This represents an increase of 512.1% from the prior year.

EBITDA

-$164.2M

AKSO HEALTH GROUP's EBITDA was -$164.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Net Income

-$135.0M

YoY-1327.0%

AKSO HEALTH GROUP reported -$135.0M in net income in fiscal year 2025. This represents a decrease of 1327.0% from the prior year.

EPS (Diluted)

$-0.16

YoY-128.6%

AKSO HEALTH GROUP earned $-0.16 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 128.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$1.0M

AKSO HEALTH GROUP generated $1.0M in free cash flow in fiscal year 2025, representing cash available after capex.

Cash & Debt

$176.2M

YoY+106.9%

5Y CAGR+92.5%

AKSO HEALTH GROUP held $176.2M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

1.66B

YoY+278.7%

5Y CAGR+102.3%

AKSO HEALTH GROUP had 1.66B shares outstanding in fiscal year 2025. This represents an increase of 278.7% from the prior year.

Margins & Returns

Gross Margin

-1.9%

YoY-7.0pp

5Y CAGR-101.9pp

AKSO HEALTH GROUP's gross margin was -1.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 7.0 percentage points from the prior year.

Operating Margin

-1125.4%

YoY-767.6pp

5Y CAGR-429.6pp

AKSO HEALTH GROUP's operating margin was -1125.4% in fiscal year 2025, reflecting core business profitability. This is down 767.6 percentage points from the prior year.

Net Margin

-913.4%

YoY-521.6pp

5Y CAGR+116.3pp

AKSO HEALTH GROUP's net profit margin was -913.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 521.6 percentage points from the prior year.

Return on Equity

-67.8%

YoY-60.9pp

5Y CAGR+80.2pp

AKSO HEALTH GROUP's ROE was -67.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 60.9 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$154K

5Y CAGR-5.1%

AKSO HEALTH GROUP invested $154K in capex in fiscal year 2025, funding long-term assets and infrastructure.

AHG Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$14.8M+512.1%	$2.4M-81.7%	$13.2M+119.7%	$6.0M+241.9%	$1.8M-74.6%	$6.9M
Cost of Revenue	$15.1M+557.0%	$2.3M-80.8%	$11.9M+120.8%	$5.4M+890.7%	$545K-47.3%	$1.0M
Gross Profit	-$282K-330.5%	$122K-90.4%	$1.3M+109.7%	$605K-65.5%	$1.8M-74.6%	$6.9M
R&D Expenses	N/A	N/A	N/A	$421K-4.6%	$441K+274.3%	$118K
SG&A Expenses	$3.6M-57.6%	$8.6M-44.7%	$15.5M+481.7%	$2.7M+31.4%	$2.0M-90.1%	$20.5M
Operating Income	-$166.3M-1825.3%	-$8.6M+39.5%	-$14.3M-337.6%	-$3.3M+23.1%	-$4.2M+91.2%	-$48.1M
Interest Expense	N/A	N/A	N/A	$804K-62.7%	$2.2M	N/A
Income Tax	-$30.8M-123363.8%	$25K+42.4%	$18K-81.1%	$93K-80.8%	$483K-1.4%	$490K
Net Income	-$135.0M-1327.0%	-$9.5M-595.5%	-$1.4M+91.9%	-$16.9M+51.6%	-$34.8M+51.1%	-$71.2M
EPS (Diluted)	$-0.16-128.6%	$-0.07-250.0%	$-0.02+92.9%	$-0.28+60.6%	$-0.71+51.4%	$-1.46

Metric	Q2'26	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

AHG Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$215.0M+51.4%	$142.0M+594.1%	$20.5M-67.4%	$62.8M+23.9%	$50.7M-37.0%	$80.5M
Current Assets	$196.1M+38.1%	$142.0M+594.1%	$20.5M-67.4%	$62.8M+108.5%	$30.1M-42.1%	$52.0M
Cash & Equivalents	$176.2M+106.9%	$85.2M+974.8%	$7.9M-57.0%	$18.4M+21.8%	$15.1M+126.9%	$6.7M
Inventory	$190K-0.5%	$191K-88.7%	$1.7M-78.4%	$7.8M	N/A	N/A
Accounts Receivable	$954K	N/A	$7.7M	N/A	N/A	N/A
Goodwill	$10.8M-79.2%	$52.1M	N/A	N/A	N/A	N/A
Total Liabilities	$15.8M+339.7%	$3.6M-69.1%	$11.6M-77.0%	$50.5M+51.2%	$33.4M+3.2%	$32.4M
Current Liabilities	$13.8M+284.3%	$3.6M-69.1%	$11.6M-77.0%	$50.5M+250.5%	$14.4M+16.6%	$12.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$199.1M+43.9%	$138.4M+1485.8%	$8.7M-29.0%	$12.3M-28.9%	$17.3M-64.1%	$48.1M
Retained Earnings	-$198.9M-211.1%	-$63.9M-17.4%	-$54.5M-2.6%	-$53.1M-46.5%	-$36.3M-2436.1%	-$1.4M

Metric	Q2'26	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22
Total Assets	$212.0M-1.4%	$215.0M+0.9%	$212.9M+49.9%	$142.0M+741.3%	$16.9M-17.5%	$20.5M-2.1%	$20.9M-66.7%	$62.8M
Current Assets	$18.4M-90.6%	$196.1M+95.7%	$100.2M-29.4%	$142.0M+741.3%	$16.9M-17.5%	$20.5M-2.0%	$20.9M-66.8%	$62.8M
Cash & Equivalents	$11.1M-93.7%	$176.2M+92.9%	$91.4M+7.3%	$85.2M+824.6%	$9.2M+16.2%	$7.9M-20.7%	$10.0M-45.8%	$18.4M
Inventory	$194K+1.9%	$190K-3.3%	$197K+2.9%	$191K-84.4%	$1.2M-27.2%	$1.7M+87.5%	$900K-88.5%	$7.8M
Accounts Receivable	$3.2M+232.2%	$954K+133.7%	$408K	N/A	$5.8M-24.3%	$7.7M	N/A	N/A
Goodwill	$11.0M+1.9%	$10.8M-90.4%	$112.5M+115.9%	$52.1M	N/A	N/A	N/A	N/A
Total Liabilities	$13.7M-13.1%	$15.8M+28.5%	$12.3M+242.2%	$3.6M-68.9%	$11.5M-0.6%	$11.6M+5.9%	$11.0M-78.3%	$50.5M
Current Liabilities	$12.0M-13.0%	$13.8M+12.9%	$12.2M+240.4%	$3.6M-68.9%	$11.5M-0.6%	$11.6M+5.9%	$11.0M-78.3%	$50.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$198.3M-0.4%	$199.1M-0.7%	$200.6M+45.0%	$138.4M+2549.0%	$5.2M-40.1%	$8.7M-12.0%	$9.9M-19.3%	$12.3M
Retained Earnings	-$200.2M-0.6%	-$198.9M-208.3%	-$64.5M-0.9%	-$63.9M-10.4%	-$57.9M-6.3%	-$54.5M-4.1%	-$52.3M+1.5%	-$53.1M

AHG Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$1.2M-12.9%	$1.4M+141.5%	-$3.3M+62.3%	-$8.6M-185.8%	$10.1M+117.3%	-$58.3M
Capital Expenditures	$154K	N/A	N/A	$5K	N/A	$200K
Free Cash Flow	$1.0M	N/A	N/A	-$8.6M	N/A	-$58.5M
Investing Cash Flow	-$105.9M-93.6%	-$54.7M-396.3%	$18.5M+192.5%	-$20.0M-3015588.8%	-$662-100.0%	$12.8M
Financing Cash Flow	$195.9M+48.8%	$131.7M+578.5%	-$27.5M-179.1%	$34.8M+484.9%	-$9.0M-482.2%	-$1.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	$2.7M

Metric	Q2'26	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

AHG Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	-1.9%-7.0pp	5.1%-4.6pp	9.6%-0.5pp	10.1%-89.9pp	100.0%0.0pp	100.0%
Operating Margin	-1125.4%-767.6pp	-357.8%-249.5pp	-108.2%-53.9pp	-54.3%+187.3pp	-241.7%+454.0pp	-695.7%
Net Margin	-913.4%-521.6pp	-391.8%-381.5pp	-10.3%+270.5pp	-280.9%+1703.7pp	-1984.5%-954.8pp	-1029.7%
Return on Equity	-67.8%-60.9pp	-6.8%+8.8pp	-15.6%+121.6pp	-137.2%+64.5pp	-201.6%-53.6pp	-148.0%
Return on Assets	-62.8%-56.1pp	-6.7%-0.0pp	-6.7%+20.2pp	-26.8%+41.9pp	-68.7%+19.8pp	-88.5%
Current Ratio	14.20-25.3	39.52+37.8	1.76+0.5	1.24-0.8	2.09-2.1	4.21
Debt-to-Equity	0.08+0.1	0.03-1.3	1.33-2.8	4.11+2.2	1.93+1.3	0.67
FCF Margin	6.9%	N/A	N/A	-143.9%	N/A	-845.8%

Metric	Q2'26	Q4'25	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	1.53-12.7	14.20+6.0	8.19-31.3	39.52+38.1	1.46-0.3	1.76-0.1	1.90+0.7	1.24
Debt-to-Equity	0.07-0.0	0.08+0.0	0.06+0.0	0.03-2.2	2.21+0.9	1.33+0.2	1.11-3.0	4.11
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Owens & Minor OMI

$216.6M

Henry Schein, Inc. HSIC

$9.6B

Quipt Home Medical Corp QIPT

$162.3M

111 YI

$35.3M

Inmode Ltd. INMD

$862.8M

Frequently Asked Questions

What is AKSO HEALTH GROUP's annual revenue?

AKSO HEALTH GROUP (AHG) reported $14.8M in total revenue for fiscal year 2025. This represents a 512.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is AKSO HEALTH GROUP's revenue growing?

AKSO HEALTH GROUP (AHG) revenue grew by 512.1% year-over-year, from $2.4M to $14.8M in fiscal year 2025.

Is AKSO HEALTH GROUP profitable?

No, AKSO HEALTH GROUP (AHG) reported a net income of -$135.0M in fiscal year 2025, with a net profit margin of -913.4%.

What is AKSO HEALTH GROUP's EBITDA?

AKSO HEALTH GROUP (AHG) had EBITDA of -$164.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is AKSO HEALTH GROUP's gross margin?

AKSO HEALTH GROUP (AHG) had a gross margin of -1.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is AKSO HEALTH GROUP's operating margin?

AKSO HEALTH GROUP (AHG) had an operating margin of -1125.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is AKSO HEALTH GROUP's net profit margin?

AKSO HEALTH GROUP (AHG) had a net profit margin of -913.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is AKSO HEALTH GROUP's return on equity (ROE)?

AKSO HEALTH GROUP (AHG) has a return on equity of -67.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is AKSO HEALTH GROUP's free cash flow?

AKSO HEALTH GROUP (AHG) generated $1.0M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is AKSO HEALTH GROUP's operating cash flow?

AKSO HEALTH GROUP (AHG) generated $1.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are AKSO HEALTH GROUP's total assets?

AKSO HEALTH GROUP (AHG) had $215.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are AKSO HEALTH GROUP's capital expenditures?

AKSO HEALTH GROUP (AHG) invested $154K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does AKSO HEALTH GROUP have outstanding?

AKSO HEALTH GROUP (AHG) had 1.66B shares outstanding as of fiscal year 2025.

What is AKSO HEALTH GROUP's current ratio?

AKSO HEALTH GROUP (AHG) had a current ratio of 14.20 as of fiscal year 2025, which is generally considered healthy.

What is AKSO HEALTH GROUP's debt-to-equity ratio?

AKSO HEALTH GROUP (AHG) had a debt-to-equity ratio of 0.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is AKSO HEALTH GROUP's return on assets (ROA)?

AKSO HEALTH GROUP (AHG) had a return on assets of -62.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is AKSO HEALTH GROUP's Altman Z-Score?

AKSO HEALTH GROUP (AHG) has an Altman Z-Score of 45.71, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is AKSO HEALTH GROUP's Piotroski F-Score?

AKSO HEALTH GROUP (AHG) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are AKSO HEALTH GROUP's earnings high quality?

AKSO HEALTH GROUP (AHG) has an earnings quality ratio of -0.01x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is AKSO HEALTH GROUP?

AKSO HEALTH GROUP (AHG) scores 56 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.